Ifosfamide in germ cell tumors

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Even in this refractory setting, we were able to cure a small cohort of patients. Ifosfamide-cisplatin combination chemotherapy then became a standard second-line chemotherapy program, and achieved a 25% cure rate. Subsequent phase III studies compared VIP to bleomycin + etoposide + cisplatin (BEP) as initial chemotherapy. Although the results of the ifosfamide-based regimen were slightly better, there was no statistically significant difference and BEP was less toxic. However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.

Original languageEnglish (US)
Pages (from-to)73-75
Number of pages3
JournalOncology
Volume65
Issue numberSUPPL. 2
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Ifosfamide
Germ Cell and Embryonal Neoplasms
Cisplatin
Etoposide
Bleomycin
Drug Therapy
Combination Drug Therapy
Pulmonary Fibrosis
Poisons

Keywords

  • Germ cell tumors
  • Ifosfamide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ifosfamide in germ cell tumors. / Einhorn, Lawrence.

In: Oncology, Vol. 65, No. SUPPL. 2, 2003, p. 73-75.

Research output: Contribution to journalArticle

Einhorn, Lawrence. / Ifosfamide in germ cell tumors. In: Oncology. 2003 ; Vol. 65, No. SUPPL. 2. pp. 73-75.
@article{a4b587b090e44da29bbf9ff87b5df162,
title = "Ifosfamide in germ cell tumors",
abstract = "Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Even in this refractory setting, we were able to cure a small cohort of patients. Ifosfamide-cisplatin combination chemotherapy then became a standard second-line chemotherapy program, and achieved a 25{\%} cure rate. Subsequent phase III studies compared VIP to bleomycin + etoposide + cisplatin (BEP) as initial chemotherapy. Although the results of the ifosfamide-based regimen were slightly better, there was no statistically significant difference and BEP was less toxic. However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.",
keywords = "Germ cell tumors, Ifosfamide",
author = "Lawrence Einhorn",
year = "2003",
doi = "10.1159/000073364",
language = "English (US)",
volume = "65",
pages = "73--75",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Ifosfamide in germ cell tumors

AU - Einhorn, Lawrence

PY - 2003

Y1 - 2003

N2 - Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Even in this refractory setting, we were able to cure a small cohort of patients. Ifosfamide-cisplatin combination chemotherapy then became a standard second-line chemotherapy program, and achieved a 25% cure rate. Subsequent phase III studies compared VIP to bleomycin + etoposide + cisplatin (BEP) as initial chemotherapy. Although the results of the ifosfamide-based regimen were slightly better, there was no statistically significant difference and BEP was less toxic. However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.

AB - Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Even in this refractory setting, we were able to cure a small cohort of patients. Ifosfamide-cisplatin combination chemotherapy then became a standard second-line chemotherapy program, and achieved a 25% cure rate. Subsequent phase III studies compared VIP to bleomycin + etoposide + cisplatin (BEP) as initial chemotherapy. Although the results of the ifosfamide-based regimen were slightly better, there was no statistically significant difference and BEP was less toxic. However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.

KW - Germ cell tumors

KW - Ifosfamide

UR - http://www.scopus.com/inward/record.url?scp=0242288530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242288530&partnerID=8YFLogxK

U2 - 10.1159/000073364

DO - 10.1159/000073364

M3 - Article

C2 - 14586153

AN - SCOPUS:0242288530

VL - 65

SP - 73

EP - 75

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - SUPPL. 2

ER -